F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
Register & Login
Kilitch Drugs (India) Ltd is an established pharmaceutical company engaged in the manufacturing and marketing of a wide range of healthcare and specialty products. Known for its strong product portfolio and growing export footprint, the company has been gradually gaining investor attention in the Indian stock market. In this article, we’ll explore Kilitch Drugs share price target from 2025 to 2030, along with its key financial metrics and future growth potential.
Kilitch Drugs Share Price Today (As of November 2025)
| Detail | Value |
|---|---|
| Open | ₹376.75 |
| Previous Close | ₹378.10 |
| Day’s High | ₹402.75 |
| Day’s Low | ₹376.75 |
| VWAP | ₹393.91 |
| 52-Week High | ₹500.00 |
| 52-Week Low | ₹299.95 |
| Market Capitalization | ₹686 Cr |
| Face Value | ₹10 |
| Book Value Per Share | ₹144.30 |
| Beta (Volatility) | 0.73 |
| 20D Avg Volume | 51,344 |
| 20D Avg Delivery (%) | 45.92% |
Kilitch Drugs currently trades near the ₹380 level, showing a steady trend after a correction from its 52-week high of ₹500. The company’s moderate beta indicates low volatility compared to the broader market, making it a relatively stable pharmaceutical stock for long-term investors.
About Kilitch Drugs (India) Ltd
Founded in 1978, Kilitch Drugs (India) Ltd is engaged in the development, production, and distribution of pharmaceutical formulations. The company operates across various therapeutic segments such as antibiotics, analgesics, vitamins, and nutraceuticals. It also exports its products to several countries in Africa, the Middle East, and Latin America.
Key Highlights
-
Diversified pharmaceutical portfolio catering to global markets.
-
Expanding presence in the African continent with joint ventures and local manufacturing units.
-
Strong R&D pipeline and focus on cost-efficient production.
-
Consistent growth in exports and branded generics.
-
Low volatility stock suitable for long-term investors.
Kilitch Drugs Shareholding Pattern (September 2025)
| Investor Type | Holding (%) |
|---|---|
| Promoters | 63.77% |
| Retail & Others | 36.23% |
The high promoter holding of nearly 64% reflects strong confidence from the management, while the significant retail participation shows growing interest among small investors.
Kilitch Drugs Share Price Target 2025 to 2030
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 410 | 440 |
| 2026 | 450 | 490 |
| 2027 | 500 | 540 |
| 2028 | 560 | 610 |
| 2029 | 620 | 680 |
| 2030 | 700 | 760 |
These projections are based on the company’s financial performance, expansion plans, export growth, and industry outlook.
Year-Wise Analysis & Investment Outlook
Kilitch Drugs Share Price Target 2025: ₹410 – ₹440
By 2025, Kilitch Drugs may regain its momentum as the company continues to focus on export markets and capacity expansion. The pharmaceutical sector’s stability is likely to support this growth.
Why:
-
Strong promoter backing and consistent operations.
-
Rising healthcare demand in African markets.
-
Good recovery potential post market consolidation.
Investment Advice: Investors can start accumulating shares at current levels for steady growth in the coming years.
Kilitch Drugs Share Price Target 2026: ₹450 – ₹490
In 2026, the company is expected to see higher profitability from its overseas ventures and growing product range.
Why:
-
Improved margins due to better capacity utilization.
-
Expansion in export partnerships.
-
Positive sentiment in the pharma sector.
Investment Advice: Hold existing positions; medium-term investors can expect gradual appreciation.
Kilitch Drugs Share Price Target 2027: ₹500 – ₹540
The year 2027 may bring steady growth backed by strong export orders and increased brand presence in developing markets.
Why:
-
Steady cash flows and controlled debt levels.
-
Broader geographical reach with product diversification.
-
Potential inclusion in institutional investor portfolios.
Investment Advice: Ideal time to hold for long-term compounding; reinvest dividends for higher returns.
Kilitch Drugs Share Price Target 2028: ₹560 – ₹610
By 2028, Kilitch Drugs may cross the ₹600 mark with continued innovation and export expansion.
Why:
-
Consistent R&D investment and product launches.
-
Stable operational efficiency and cost management.
-
Better market valuation driven by growth consistency.
Investment Advice: Continue holding for 2–3 more years to maximize compounding potential.
Kilitch Drugs Share Price Target 2029: ₹620 – ₹680
In 2029, Kilitch Drugs could strengthen its balance sheet and achieve higher profitability through strategic alliances.
Why:
-
Rising export contribution to total revenue.
-
Possible entry into new therapeutic categories.
-
Increasing dividend payout ratio.
Investment Advice: Suitable for long-term investors aiming for stable and moderate returns.
Kilitch Drugs Share Price Target 2030: ₹700 – ₹760
By 2030, Kilitch Drugs (India) Ltd could emerge as a significant mid-cap pharma player with a global presence.
Why:
-
Continuous innovation and export expansion.
-
Strong fundamentals with improving book value.
-
Potential re-rating in market valuation.
Investment Advice: Excellent choice for long-term investors seeking value creation in the healthcare segment.
Should You Invest in Kilitch Drugs (India) Ltd for the Long Term?
Yes, Kilitch Drugs can be considered a good long-term investment for investors who prefer stability and gradual growth. Its strong promoter holding, steady financials, and expanding global reach make it a promising pharma stock.
Key Reasons to Invest:
-
Expanding global footprint in the pharmaceutical export market.
-
Solid book value and consistent operational performance.
-
Steady dividends and low market volatility.
Risks to Watch Out For:
-
Regulatory challenges in export markets.
-
Competition from large pharmaceutical players.
-
Currency fluctuations affecting export revenue.
Conclusion
Kilitch Drugs (India) Ltd is a steadily growing pharmaceutical company with strong fundamentals and global expansion strategies. With a current price of around ₹380, the stock has shown resilience and has the potential to reach ₹760 by 2030 if growth trends continue.
For investors seeking a mix of safety, consistent returns, and long-term potential, Kilitch Drugs can be a strong addition to a diversified portfolio.
Stay updated with quarterly financial results and monitor stock performance between April and December for strategic investment entries.
Frequently Asked Questions (FAQs) about Kilitch Drugs (India) Ltd
1. What is the current share price of Kilitch Drugs (India) Ltd?
The current share price is around ₹380 as of November 2025.
2. What is the 52-week high and low of Kilitch Drugs?
The 52-week high is ₹500, and the 52-week low is ₹299.95.
3. What is the share price target for Kilitch Drugs in 2025?
The 2025 share price target is between ₹410 and ₹440.
4. Is Kilitch Drugs a good stock for long-term investment?
Yes, due to its strong promoter holding, export growth, and stable fundamentals, it is a good option for long-term investors.
5. What is the market cap of Kilitch Drugs (India) Ltd?
As of November 2025, the company’s market capitalization stands at ₹686 crore.
6. What is Kilitch Drugs’ all-time high?
The all-time high for Kilitch Drugs is ₹500.
7. What is the promoter holding in Kilitch Drugs?
Promoters hold about 63.77% of the total shares.
8. What is the dividend yield of Kilitch Drugs?
The company offers a steady dividend yield, aligning with its stable profitability.
9. What are the major business segments of Kilitch Drugs?
The company operates across formulations, generics, and export markets, especially in Africa and the Middle East.
10. Should I buy Kilitch Drugs stock now?
Investors can consider buying in small quantities during market dips for long-term portfolio growth.
Disclaimer: This article is for educational and informational purposes only. It is not investment advice. Please consult your financial advisor before making any stock market investments.
